The current standard therapy for chronic hepatitis C is pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Recently, it has been reported that amino acid (aa) substitutions in the core region, as well as the IFN-sensitivity-determining region (ISDR), were predictive of non-virological response (NVR), sustained virological response (SVR) and early virological response. Despite the importance of these two predictive factors for combination therapy, their interaction is poorly understood.
Methods
A total of 117 patients who were treated with PEG-IFN-α2b plus RBV combination therapy were selected for participation in this study. We determined the aa sequences in the core region and ISDR by direct sequencing and analysed them along with clinical data to indentify predictive factors for therapeutic response.
Results
The aa sequences in the core region and γ-glutamyl transpeptidase (GTP) levels were associated with SVR and NVR, but aa sequences in the ISDR were not. However, substitutions at both aa 70 and aa 91 in the core region without substitutions in the ISDR and higher levels of γ-GTP were independent predictive factors for NVR. Wild-type aa 70 and aa 91 in the core region, higher platelet counts and lower levels of γ-GTP were independent predictive factors for SVR.
Conclusions
These results indicate that analyses of aa substitutions in both the core region and the ISDR are useful for predicting the effectiveness of combination therapy, and could help to avoid therapy exposure for patients who have a low probability of SVR.
References
1.
AlterH.J., PurcellR.H., ShihJ.W.Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.N Engl J Med1989; 321: 1494–1500.
2.
CooperS., EricksonA.L., AdamsE.J.Analysis of a successful immune response against hepatitis C virus.Immunity1999; 10: 439–449.
3.
LeeS.H., KimY.K., KimC.S.E2 of hepatitis C virus inhibits apoptosis.J Immunol2005; 175: 8226–8235.
4.
AkutaN., ChayamaK., SuzukiF.Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 allele.J Med Virol2001; 64: 109–116.
5.
DusheikoG.M.The natural course of chronic hepatitis C: implications for clinical practice.J Viral Hepat1998; 5 Suppl 1: 9–12.
6.
IkedaK., SaitohS., SuzukiY.Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.J Hepatol1998; 28: 930–938.
7.
Kenny-WalshE.Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.N Engl J Med1999; 340: 1228–1233.
8.
NiederauC., LangeS., HeintgesT.Prognosis of chronic hepatitis C: results of a large, prospective cohort study.Hepatology1998; 28: 1687–1695.
9.
DavisG.L., BalartL.A., SchiffE.R.Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group.N Engl J Med1989; 321: 1501–1506.
10.
Di BisceglieA.M., MartinP., KassianidesC.Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.N Engl J Med1989; 321: 1506–1510.
11.
DavisG.L., Esteban-MurR., RustgiV.Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.N Engl J Med1998; 339: 1493–1499.
12.
McHutchisonJ.G., GordonS.C., SchiffE.R.Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.N Engl J Med1998; 339: 1485–1492.
13.
ReichardO., NorkransG., FrydenA., BraconierJ.H., SonnerborgA., WeilandO.Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.Lancet1998; 351: 83–87.
14.
SchalmS.W., HansenB.E., ChemelloL.Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.J Hepatol1997; 26: 961–966.
15.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med2002; 347: 975–982.
16.
HoofnagleJ.H., GhanyM.G., KleinerD.E.Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.Hepatology2003; 38: 66–74.
17.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
18.
AkutaN., SuzukiF., KawamuraY.Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.J Med Virol2007; 79: 1686–1695.
19.
AkutaN., SuzukiF., KawamuraY.Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.J Hepatol2007; 46: 403–410.
20.
ConjeevaramH.S., FriedM.W., JeffersL.J.Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.Gastroenterology2006; 131: 470–477.
21.
HiramatsuN., OzeT., TsudaN.Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?Hepatol Res2006; 35: 185–189.
22.
SezakiH., SuzukiF., KawamuraY.Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads.Dig Dis Sci200954: 1317–1324.
23.
HiramatsuN., KurashigeN., OzeT.Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C.Hepatol Res2008; 38: 52–59.
24.
AbbateI., Lo IaconoO., Di StefanoR.HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.J Hepatol2004; 40: 831–836.
25.
YenY.H., HungC.H., HuT.H.Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.Aliment Pharmacol Ther2008; 27: 72–79.
26.
AkutaN., SuzukiF., HirakawaM.A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.J Med Virol2009; 81: 452–458.
27.
AkutaN., SuzukiF., KawamuraY.Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.Intervirology2007; 50: 361–368.
28.
OkanoueT., ItohY., HashimotoH.Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.J Gastroenterol2009; 44: 952–963.
29.
MoriN., ImamuraM., KawakamiY.Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.J Med Virol2009; 81: 640–649.
30.
KumadaH., OkanoueT., OnjiM.Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan.Hepatol Res2010; 40: 8–13.
31.
LoguercioC., Di PierroM., Di MarinoM.P.Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects.Alcohol Alcohol2000; 35: 296–301.
32.
AkutaN., SuzukiF., SezakiH.Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.J Med Virol2006; 78: 83–90.
33.
AkutaN., SuzukiF., SezakiH.Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.Intervirology2005; 48: 372–380.
34.
KatoN., HijikataM., OotsuyamaY.Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.Proc Natl Acad Sci U S A1990; 87: 9524–9528.
35.
HadziyannisS.J., SetteH.Jr., MorganT.R.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med2004; 140: 346–355.
36.
EnomotoN., SakumaI., AsahinaY.Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.N Engl J Med1996; 334: 77–81.
37.
ChayamaK., TsubotaA., KobayashiM.Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.Hepatology1997; 25: 745–749.
38.
KurosakiM., EnomotoN., MurakamiT.Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.Hepatology1997; 25: 750–753.
39.
NagayamaK., EnomotoN., IzumiN.Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients.Gut2001; 48: 830–835.
40.
WatanabeH., EnomotoN., NagayamaK.Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection.J Infect Dis2001; 183: 1195–1203.
41.
HiragaN., ImamuraM., TsugeM.Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon.FEBS Lett2007; 581: 1983–1987.
42.
KimuraT., ImamuraM., HiragaN.Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice.J Gen Virol2008; 89: 2108–2113.
43.
AlexanderW.S.Suppressors of cytokine signalling (SOCS) in the immune system.Nat Rev Immunol2002; 2: 410–416.
44.
AuernhammerC.J., BousquetC., ChesnokovaV., MelmedS.SOCS proteins: modulators of neuroimmunoendocrine functions. Impact on corticotroph LIF signaling.Ann N Y Acad Sci2000; 917: 658–664.
45.
FujimotoM., NakaT.Regulation of cytokine signaling by SOCS family molecules.Trends Immunol2003; 24: 659–666.
46.
SamuelC.E.Antiviral actions of interferons.Clin Microbiol Rev2001; 14: 778–809.
47.
SenG.C.Viruses and interferons.Annu Rev Microbiol2001; 55: 255–281.
48.
SongM.M., ShuaiK.The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities.J Biol Chem1998; 273: 35056–35062.
49.
StoiberD., KovarikP., CohneyS., JohnstonJ.A., SteinleinP., DeckerT.Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma.J Immunol1999; 163: 2640–2647.
50.
VlotidesG., SorensenA.S., KoppF.SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA.Biochem Biophys Res Commun2004; 320: 1007–1014.
51.
BodeJ.G., LudwigS., EhrhardtC.IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3.FASEB J2003; 17: 488–490.
52.
GaleM.Jr., BlakelyC.M., KwieciszewskiB.Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation.Mol Cell Biol1998; 18: 5208–5218.
53.
PolyakS.J., KhabarK.S., PaschalD.M.Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response.J Virol2001; 75: 6095–6106.
54.
PolyakS.J., KhabarK.S., RezeiqM., GretchD.R.Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy.J Virol2001; 75: 6209–6211.
55.
TaguchiT., Nagano-FujiiM., AkutsuM.Hepatitis C virus NS5A protein interacts with 2’,5’-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner.J Gen Virol2004; 85: 959–969.
